Skip to main content
×
×
Home

Successful clozapine re-challenge in a patient with three previous episodes of clozapine-associated blood dyscrasia

  • Jessica Foster (a1), John Lally (a2), Victoria Bell (a1) and Sukhi Shergill (a3)
Abstract

A case is presented of a 30-year-old female with treatment-resistant schizoaffective disorder who was referred to a tertiary-level specialist psychosis service. We describe the history of clozapine trials and associated episodes of agranulocytosis and neutropenia, followed by the successfully tolerated third clozapine re-challenge within our service.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Successful clozapine re-challenge in a patient with three previous episodes of clozapine-associated blood dyscrasia
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Successful clozapine re-challenge in a patient with three previous episodes of clozapine-associated blood dyscrasia
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Successful clozapine re-challenge in a patient with three previous episodes of clozapine-associated blood dyscrasia
      Available formats
      ×
Copyright
This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) license.
Corresponding author
Correspondence: John Lally, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London SE5 8AF, UK. Email: john.lally@kcl.ac.uk
Footnotes
Hide All

These authors contributed equally to the work.

Declaration of interest

None.

Footnotes
References
Hide All
1 National Collaborating Centre for Mental Health. Psychosis and Schizophrenia in Adults: Treatment and Management. Clinical Guideline 178. NICE, 2014.
2 Meltzer, HY. Treatment-resistant schizophrenia – the role of clozapine. Curr Med Res Opinion 1997; 14: 120.
3 Meltzer, HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 1992; 18: 51–42.
4 Alvir, JM, Lieberman, JA, Safferman, AZ, Schwimmer, JL, Schaaf, JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162–7.
5 Dunk, LR, Annan, LJ, Andrews, CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006; 188: 255–63.
6 Rostami-Hodjegan, A, Amin, AM, Spencer, EP, Lennard, MS, Tucker, GT, Flanagan, RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004; 24: 70–8.
7 Taylor, D, Paton, C, Kapur, S. The Maudsley Prescribing Guidelines in Psychiatry. 12th edn. Wiley Blackwell, 2015.
8 Manu, P, Sarpal, D, Muir, O, Kane, JM, Correll, CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 2012; 134: 180–6.
9 Meyer, N, Gee, S, Whiskey, E, Taylor, D, Mijovic, A, Gaughran, F, et al. Optimizing outcomes in clozapine rechallenge following neuttropenia: a cohort analysis. J Clin Psychiatry 2015; 76: 1410–6.
10 Correll, CU, Gallego, JA. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am 2012; 35: 661–81.
11 Mintzer, DM, Billet, SN, Chmielewski, L. Drug-induced hematologic syndromes. Adv Hematol 2009; 2009: 495863.
12 Murphy, DL, Goodwin, FK, Bunney, WE Jr. Leukocytosis during lithium treatment. Am J Psychiatry 1971; 127: 1559–61.
13 Tisman, G, Herbert, V, Rosenblatt, S. Evidence that lithium induces human granulocyte proliferation: elevated serum vitamin B12 binding capacity in vivo and granulocyte colony proliferation in vitro. Br J Haematol 1973; 24: 767–71.
14 Blier, P, Slater, S, Measham, T, Koch, M, Wiviott, G. Lithium and clozapine-induced neutropenia/agranulocytosis. Int Clin Psychopharmacol 1998; 13: 137–40.
15 Whiskey, E, Taylor, D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs 2007; 21: 2535.
16 Goldstein, JI, Jarskog, LF, Hilliard, C, Alfirevic, A, Duncan, L, Fourches, D, et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun 2014; 5: 4757.
17 Pereira, A, Dean, B. Clozapine bioactivation induces dose-dependent, drug-specific toxicity of human bone marrow stromal cells: a potential in vitro system for the study of agranulocytosis. Biochem Pharmacol 2006; 72: 783–93.
18 Duggal, HS, Singh, I. Psychotropic drug-induced neutropenia. Drugs Today 2005; 41: 517–26.
19 Fehsel, K, Loeffler, S, Krieger, K, Henning, U, Agelink, M, Kolb-Bachofen, V, et al. Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. J Clin Psychopharmacol 2005; 25: 419–26.
20 R⊘ge, R, M⊘ller, BK, Andersen, CR, Correll, CU, Nielsen, J. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res 2012; 140: 204–13.
21 Haddy, TB, Rana, SR, Castro, O. Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 1999; 133: 1522.
22 Flanagan, RJ, Dunk, L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008; 23 (Suppl 1): 2741.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Open
  • ISSN: -
  • EISSN: 2056-4724
  • URL: /core/journals/bjpsych-open
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 1
Total number of PDF views: 20 *
Loading metrics...

Abstract views

Total abstract views: 77 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 17th July 2018. This data will be updated every 24 hours.

Successful clozapine re-challenge in a patient with three previous episodes of clozapine-associated blood dyscrasia

  • Jessica Foster (a1), John Lally (a2), Victoria Bell (a1) and Sukhi Shergill (a3)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *